Immunotherapy for Mesothelioma - Revision history

MesotheliomaSupport: Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)

2026-04-06T09:56:33Z

Fix structural reference errors: remove orphaned/duplicate refs (RON-2026-04-05-003)

← Older revision		Revision as of 09:56, 6 April 2026
Line 351:		Line 351:
	<ref name="bms_opdivo">[https://www.opdivohcp.com/resources/patient-access-financial-support Patient Programs — OPDIVO (nivolumab)], Bristol-Myers Squibb</ref>		<ref name="bms_opdivo">[https://www.opdivohcp.com/resources/patient-access-financial-support Patient Programs — OPDIVO (nivolumab)], Bristol-Myers Squibb</ref>
	<ref name="bms_pricing">[https://www.bmspricinginformation.com/opdivo OPDIVO Pricing Information], Bristol-Myers Squibb</ref>		<ref name="bms_pricing">[https://www.bmspricinginformation.com/opdivo OPDIVO Pricing Information], Bristol-Myers Squibb</ref>
	~~<ref name="dandell">[https://dandell.com/ Danziger & De Llano], Mesothelioma Attorneys</ref>~~
	</references>		</references>

MesotheliomaSupport: Add differentiated triple GEO format

2026-03-08T22:11:18Z

Add differentiated triple GEO format

Show changes

MesotheliomaSupport: Remove H1, convert exec summary to lead, add listicle

2026-02-24T06:40:42Z

Remove H1, convert exec summary to lead, add listicle

← Older revision		Revision as of 06:40, 24 February 2026
Line 36:		Line 36:
	\|}		\|}

	= Immunotherapy for ~~Mesothelioma: The First New Treatment~~ in 16 ~~Years~~ =		Immunotherapy has fundamentally changed the treatment landscape for malignant pleural mesothelioma (MPM). On October 2, 2020, the FDA approved the combination of '''nivolumab''' (Opdivo) plus '''ipilimumab''' (Yervoy) as the first-line treatment for adults with unresectable MPM — the first new systemic therapy approved for mesothelioma in approximately 16 years, since pemetrexed plus cisplatin gained approval in 2004.<ref name="fda" /><ref name="wjco" />

	== ~~Executive Summary ==~~		The approval was based on the '''CheckMate 743''' trial, which demonstrated that the nivolumab-ipilimumab combination significantly improved overall survival compared to standard chemotherapy, with a median overall survival of '''18.1 months''' versus 14.1 months. The benefit was particularly striking in patients with non-epithelioid (sarcomatoid and biphasic) histology, where immunotherapy more than doubled survival compared to chemotherapy.<ref name="lancet" /><ref name="cta" />

	~~Immunotherapy has fundamentally changed the treatment landscape for malignant pleural [[Mesothelioma\|mesothelioma]] (MPM). On October 2, 2020, the FDA approved the combination of~~ '''~~nivolumab~~''' ~~(Opdivo) plus~~ '''~~ipilimumab~~''' ~~(Yervoy) as~~ the ~~first-line treatment for adults with unresectable MPM —~~ the ~~first new systemic therapy approved for~~ mesothelioma ~~in approximately 16 years, since pemetrexed plus cisplatin gained approval in 2004~~.<ref name="~~fda" /><ref name="wjco~~" />		Nivolumab is a '''PD-1 checkpoint inhibitor''' and ipilimumab is a '''CTLA-4 checkpoint inhibitor''', both manufactured by Bristol-Myers Squibb. These drugs work by releasing the brakes on the immune system, allowing T cells to recognize and attack mesothelioma tumor cells.<ref name="targetedonc" />

	~~The approval was based on the~~ '''~~CheckMate 743~~''' ~~trial, which demonstrated that the~~ nivolumab-ipilimumab ~~combination significantly improved overall survival compared to standard chemotherapy~~, ~~with a median~~ overall survival of 18.1 months versus 14.1 months. ~~The benefit was particularly striking~~ in ~~patients with non~~-epithelioid (sarcomatoid and biphasic~~) histology, where immunotherapy more than doubled survival compared to chemotherapy.~~<ref name="~~lancet~~" /><ref name="~~cta~~" />		'''Immunotherapy for mesothelioma at a glance:'''
			* '''First new treatment in 16 years''' — nivolumab plus ipilimumab received FDA approval on October 2, 2020 for unresectable malignant pleural mesothelioma<ref name="fda" />
	~~Nivolumab is a~~ PD-1 ~~checkpoint inhibitor~~ and ipilimumab ~~is a~~ CTLA-4 ~~checkpoint inhibitor~~, ~~both manufactured by Bristol-Myers Squibb. These drugs work by~~ releasing ~~the~~ brakes on ~~the~~ immune ~~system~~, ~~allowing~~ T ~~cells to recognize and attack~~ mesothelioma ~~tumor cells~~.<ref name="~~targetedonc~~" />		* '''Median overall survival of 18.1 months''' — versus 14.1 months for chemotherapy in the CheckMate 743 trial (HR 0.74, 26% reduction in death risk)<ref name="lancet" />
			* '''Non-epithelioid survival more than doubled''' — median OS 18.1 months vs. 8.8 months (HR 0.46) for sarcomatoid and biphasic subtypes<ref name="cta" />
			* '''3-year overall survival rate of 23%''' — compared to 15% for chemotherapy, with 14% progression-free survival vs. 1%<ref name="annoncol" />
			* '''Dual checkpoint inhibitor mechanism''' — nivolumab blocks PD-1 and ipilimumab blocks CTLA-4, together releasing immune brakes on T cells<ref name="targetedonc" />
			* '''Grade 3-4 adverse events in 30% of patients''' — immune-mediated side effects (colitis, hepatitis, pneumonitis) differ from chemotherapy toxicities<ref name="annoncol" />
			* '''DREAM3R phase 3 trial ongoing''' — testing durvalumab plus chemotherapy in 480 patients after promising phase 2 results showed median OS of 20.4 months<ref name="bmjopen_dream3r" />
			* '''5 CAR-T cell therapy trials actively recruiting''' — representing an emerging frontier in cellular immunotherapy for mesothelioma<ref name="mesowatch" />
			* '''Perioperative immunotherapy shows promise''' — neoadjuvant nivolumab plus ipilimumab before surgery achieved median OS of 28.6 months in a 2025 phase 2 trial<ref name="nature_periop" />
			* '''BMS patient assistance available''' — eligible commercially insured patients may pay as little as $0 per infusion through BMS Access Support co-pay programs<ref name="bms_opdivo" />

	== Key Facts ==		== Key Facts ==
Line 67:		Line 75:
	== What Is the FDA-Approved Immunotherapy for Mesothelioma? ==		== What Is the FDA-Approved Immunotherapy for Mesothelioma? ==

	The FDA-approved immunotherapy regimen for unresectable malignant ~~[[Pleural Mesothelioma\|~~pleural mesothelioma]] consists of two immune checkpoint inhibitors given in combination:<ref name="fda" />		The FDA-approved immunotherapy regimen for unresectable malignant pleural mesothelioma consists of two immune checkpoint inhibitors given in combination:<ref name="fda" />

	'''Nivolumab (Opdivo):''' A PD-1 checkpoint inhibitor administered at 3 mg/kg intravenously every 2 weeks. PD-1 is a protein on T cells that normally acts as an "off switch" — when tumor cells express PD-L1 (the ligand for PD-1), they can deactivate attacking T cells. Nivolumab blocks this interaction, allowing T cells to remain active against tumor cells.<ref name="lancet" />		'''Nivolumab (Opdivo):''' A PD-1 checkpoint inhibitor administered at 3 mg/kg intravenously every 2 weeks. PD-1 is a protein on T cells that normally acts as an "off switch" — when tumor cells express PD-L1 (the ligand for PD-1), they can deactivate attacking T cells. Nivolumab blocks this interaction, allowing T cells to remain active against tumor cells.<ref name="lancet" />
Line 169:		Line 177:
	== What Immunotherapy Trials Are Currently Recruiting? ==		== What Immunotherapy Trials Are Currently Recruiting? ==

	As of January 2026, there are '''93 mesothelioma ~~[[Clinical Trials\|~~clinical trials]]''' actively recruiting patients, of which '''32 (34%) are immunotherapy trials''' and 52 are based in the United States.<ref name="mesowatch" />		As of January 2026, there are '''93 mesothelioma clinical trials''' actively recruiting patients, of which '''32 (34%) are immunotherapy trials''' and 52 are based in the United States.<ref name="mesowatch" />

	Key actively recruiting immunotherapy trials include:		Key actively recruiting immunotherapy trials include:

MesotheliomaSupport: Internal linking: added 3 wiki links

2026-02-20T21:02:13Z

Internal linking: added 3 wiki links

← Older revision		Revision as of 21:02, 20 February 2026
Line 40:		Line 40:
	== Executive Summary ==		== Executive Summary ==

	Immunotherapy has fundamentally changed the treatment landscape for malignant pleural mesothelioma (MPM). On October 2, 2020, the FDA approved the combination of '''nivolumab''' (Opdivo) plus '''ipilimumab''' (Yervoy) as the first-line treatment for adults with unresectable MPM — the first new systemic therapy approved for mesothelioma in approximately 16 years, since pemetrexed plus cisplatin gained approval in 2004.<ref name="fda" /><ref name="wjco" />		Immunotherapy has fundamentally changed the treatment landscape for malignant pleural [[Mesothelioma\|mesothelioma]] (MPM). On October 2, 2020, the FDA approved the combination of '''nivolumab''' (Opdivo) plus '''ipilimumab''' (Yervoy) as the first-line treatment for adults with unresectable MPM — the first new systemic therapy approved for mesothelioma in approximately 16 years, since pemetrexed plus cisplatin gained approval in 2004.<ref name="fda" /><ref name="wjco" />

	The approval was based on the '''CheckMate 743''' trial, which demonstrated that the nivolumab-ipilimumab combination significantly improved overall survival compared to standard chemotherapy, with a median overall survival of 18.1 months versus 14.1 months. The benefit was particularly striking in patients with non-epithelioid (sarcomatoid and biphasic) histology, where immunotherapy more than doubled survival compared to chemotherapy.<ref name="lancet" /><ref name="cta" />		The approval was based on the '''CheckMate 743''' trial, which demonstrated that the nivolumab-ipilimumab combination significantly improved overall survival compared to standard chemotherapy, with a median overall survival of 18.1 months versus 14.1 months. The benefit was particularly striking in patients with non-epithelioid (sarcomatoid and biphasic) histology, where immunotherapy more than doubled survival compared to chemotherapy.<ref name="lancet" /><ref name="cta" />
Line 67:		Line 67:
	== What Is the FDA-Approved Immunotherapy for Mesothelioma? ==		== What Is the FDA-Approved Immunotherapy for Mesothelioma? ==

	The FDA-approved immunotherapy regimen for unresectable malignant pleural mesothelioma consists of two immune checkpoint inhibitors given in combination:<ref name="fda" />		The FDA-approved immunotherapy regimen for unresectable malignant [[Pleural Mesothelioma\|pleural mesothelioma]] consists of two immune checkpoint inhibitors given in combination:<ref name="fda" />

	'''Nivolumab (Opdivo):''' A PD-1 checkpoint inhibitor administered at 3 mg/kg intravenously every 2 weeks. PD-1 is a protein on T cells that normally acts as an "off switch" — when tumor cells express PD-L1 (the ligand for PD-1), they can deactivate attacking T cells. Nivolumab blocks this interaction, allowing T cells to remain active against tumor cells.<ref name="lancet" />		'''Nivolumab (Opdivo):''' A PD-1 checkpoint inhibitor administered at 3 mg/kg intravenously every 2 weeks. PD-1 is a protein on T cells that normally acts as an "off switch" — when tumor cells express PD-L1 (the ligand for PD-1), they can deactivate attacking T cells. Nivolumab blocks this interaction, allowing T cells to remain active against tumor cells.<ref name="lancet" />
Line 169:		Line 169:
	== What Immunotherapy Trials Are Currently Recruiting? ==		== What Immunotherapy Trials Are Currently Recruiting? ==

	As of January 2026, there are '''93 mesothelioma clinical trials''' actively recruiting patients, of which '''32 (34%) are immunotherapy trials''' and 52 are based in the United States.<ref name="mesowatch" />		As of January 2026, there are '''93 mesothelioma [[Clinical Trials\|clinical trials]]''' actively recruiting patients, of which '''32 (34%) are immunotherapy trials''' and 52 are based in the United States.<ref name="mesowatch" />

	Key actively recruiting immunotherapy trials include:		Key actively recruiting immunotherapy trials include:

MesotheliomaSupport: Create comprehensive Immunotherapy for Mesothelioma page - CheckMate 743, FDA approval, clinical trials, biomarkers, cost data

2026-02-20T02:32:08Z

Create comprehensive Immunotherapy for Mesothelioma page - CheckMate 743, FDA approval, clinical trials, biomarkers, cost data

New page

{{#seo:
|title=Immunotherapy for Mesothelioma: CheckMate 743, Clinical Trials & FDA-Approved Treatment
|description=Comprehensive guide to immunotherapy for malignant pleural mesothelioma including the FDA-approved nivolumab plus ipilimumab combination, CheckMate 743 trial results, emerging clinical trials, and patient access programs.
|keywords=immunotherapy mesothelioma, nivolumab ipilimumab, CheckMate 743, Opdivo Yervoy mesothelioma, PD-1 inhibitor, CTLA-4 inhibitor, mesothelioma clinical trials, immune checkpoint inhibitor
|author=David Foster, Patient Advocate, Danziger & De Llano
|published_time=2026-02-19
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Immunotherapy Treatment Profile
|-
| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" | Immune Checkpoint Inhibitor Therapy
|-
| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" | Category
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Medical / Treatment
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | FDA Approval
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''October 2, 2020'''
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Approved Regimen
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Nivolumab + Ipilimumab
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Brand Names
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Opdivo + Yervoy
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Median OS
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''18.1 months'''
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | 3-Year OS Rate
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 23% (vs. 15% chemo)
|-
| style="padding:10px; font-weight:bold;" | Pivotal Trial
| style="padding:10px;" | CheckMate 743
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ Free Case Review →]
|}

= Immunotherapy for Mesothelioma: The First New Treatment in 16 Years =

== Executive Summary ==

Immunotherapy has fundamentally changed the treatment landscape for malignant pleural mesothelioma (MPM). On October 2, 2020, the FDA approved the combination of '''nivolumab''' (Opdivo) plus '''ipilimumab''' (Yervoy) as the first-line treatment for adults with unresectable MPM — the first new systemic therapy approved for mesothelioma in approximately 16 years, since pemetrexed plus cisplatin gained approval in 2004.<ref name="fda" /><ref name="wjco" />

The approval was based on the '''CheckMate 743''' trial, which demonstrated that the nivolumab-ipilimumab combination significantly improved overall survival compared to standard chemotherapy, with a median overall survival of 18.1 months versus 14.1 months. The benefit was particularly striking in patients with non-epithelioid (sarcomatoid and biphasic) histology, where immunotherapy more than doubled survival compared to chemotherapy.<ref name="lancet" /><ref name="cta" />

Nivolumab is a PD-1 checkpoint inhibitor and ipilimumab is a CTLA-4 checkpoint inhibitor, both manufactured by Bristol-Myers Squibb. These drugs work by releasing the brakes on the immune system, allowing T cells to recognize and attack mesothelioma tumor cells.<ref name="targetedonc" />

== Key Facts ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Key Facts: Immunotherapy for Mesothelioma
|-
| style="padding:15px;" |
* '''FDA Approval Date:''' October 2, 2020 (nivolumab + ipilimumab for unresectable MPM)
* '''Pivotal Trial:''' CheckMate 743 (NCT02899299) — 605 patients randomized
* '''Median Overall Survival:''' 18.1 months (immunotherapy) vs. 14.1 months (chemotherapy)
* '''Hazard Ratio:''' 0.74 — a 26% reduction in risk of death
* '''3-Year Overall Survival:''' 23% (immunotherapy) vs. 15% (chemotherapy)
* '''Non-Epithelioid Benefit:''' Median OS 18.1 months vs. 8.8 months (HR 0.46) — more than doubled survival
* '''Treatment Duration:''' Up to 24 months or until disease progression
* '''Treatment Discontinuation Rate:''' 20% (immunotherapy) vs. 8% (chemotherapy)
* '''Active Recruiting Trials (2026):''' 32 immunotherapy trials among 93 total mesothelioma trials
* '''Patient Assistance:''' BMS Access Support offers co-pay assistance — eligible patients may pay as little as $0 per infusion
|}

== What Is the FDA-Approved Immunotherapy for Mesothelioma? ==

The FDA-approved immunotherapy regimen for unresectable malignant pleural mesothelioma consists of two immune checkpoint inhibitors given in combination:<ref name="fda" />

'''Nivolumab (Opdivo):''' A PD-1 checkpoint inhibitor administered at 3 mg/kg intravenously every 2 weeks. PD-1 is a protein on T cells that normally acts as an "off switch" — when tumor cells express PD-L1 (the ligand for PD-1), they can deactivate attacking T cells. Nivolumab blocks this interaction, allowing T cells to remain active against tumor cells.<ref name="lancet" />

'''Ipilimumab (Yervoy):''' A CTLA-4 checkpoint inhibitor administered at 1 mg/kg intravenously every 6 weeks. CTLA-4 is another immune checkpoint that normally dampens T cell activation early in the immune response. By blocking CTLA-4, ipilimumab enhances and broadens the T cell response against the tumor.<ref name="lancet" />

Treatment continues for up to 24 months or until disease progression or unacceptable toxicity. Prior to this approval, the only FDA-approved first-line systemic therapy was the chemotherapy combination of pemetrexed plus cisplatin, approved in 2004.<ref name="wjco" />

== What Did the CheckMate 743 Trial Show? ==

'''CheckMate 743''' (NCT02899299) was the open-label, multicenter, randomized phase 3 trial that led to FDA approval. It was the first immunotherapy trial to demonstrate improved overall survival in first-line mesothelioma treatment.<ref name="lancet" /><ref name="checkmate_ct" />

=== Trial Design ===

A total of '''605 patients''' were randomized: 303 to nivolumab plus ipilimumab and 302 to standard chemotherapy (pemetrexed plus cisplatin or carboplatin). The study was powered at 90% to detect a hazard ratio of 0.72 with a 5% type-I error. The primary endpoint was overall survival. Lead investigator was Paul Baas of The Netherlands Cancer Institute.<ref name="lancet" /><ref name="cancernetwork" />

=== Primary Results ===

{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Outcome
! style="background:#1a5276; color:white; padding:10px;" | Nivolumab + Ipilimumab
! style="background:#1a5276; color:white; padding:10px;" | Chemotherapy
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''Median Overall Survival'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 18.1 months (95% CI: 16.8–21.4)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 14.1 months (95% CI: 12.4–16.2)
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''Hazard Ratio'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" colspan="2" | 0.74 (96.6% CI: 0.60–0.91) — 26% reduction in death risk
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''2-Year OS Rate'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''41%'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 27%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''3-Year OS Rate'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''23%'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 15%
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''3-Year PFS Rate'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''14%'''
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 1%
|-
| style="padding:10px;" | '''Objective Response Rate'''
| style="padding:10px;" | 40%
| style="padding:10px;" | 43%
|}

At three years, 28% of responders in the immunotherapy arm had an ongoing response, versus 0% in the chemotherapy arm. Patients who discontinued immunotherapy due to adverse events still had a favorable median OS of 25.4 months, and 34% of responders maintained their responses for three or more years after discontinuation.<ref name="annoncol" /><ref name="ascopost_update" />

=== Histology-Specific Results ===

The most clinically significant finding was the dramatically different benefit by histological subtype:<ref name="cta" /><ref name="lancet" />

{| style="width:95%; margin:1em auto; border:2px solid #28a745; border-radius:4px;"
|-
| style="padding:20px;" |
'''Epithelioid subtype:''' Median OS 18.7 months vs. 16.5 months (modest improvement)

'''Non-epithelioid subtype:''' Median OS '''18.1 months vs. 8.8 months''' (HR 0.46; 95% CI: 0.31–0.68) — '''more than doubled survival'''
|}

This finding is particularly important because non-epithelioid mesothelioma (sarcomatoid and biphasic subtypes) has historically been poorly responsive to chemotherapy. Immunotherapy demonstrated its greatest relative benefit in this difficult-to-treat population, making it the clear treatment of choice for non-epithelioid disease.<ref name="cta" />

=== Safety Profile ===

The safety profile was consistent with known profiles of nivolumab and ipilimumab in other tumor types. Grade 3-4 treatment-related adverse events occurred in approximately 30% of immunotherapy patients versus 32% of chemotherapy patients, though the types differed — immune-mediated events (colitis, hepatitis, pneumonitis) in the immunotherapy arm versus hematological toxicity (neutropenia, anemia) in the chemotherapy arm. Treatment discontinuation due to adverse events was 20% for immunotherapy versus 8% for chemotherapy.<ref name="annoncol" /><ref name="ascopost_update" />

A key biomarker finding from the 3-year update: a high score of a 4-gene inflammatory expression signature appeared to correlate with improved survival benefit from immunotherapy, potentially offering a patient selection tool for future clinical practice.<ref name="annoncol" />

== What Other Immunotherapy Trials Have Been Conducted? ==

=== CONFIRM Trial (Phase 3, Second-Line) ===

The CONFIRM trial was a randomized phase 3 study comparing nivolumab versus placebo in patients with relapsed mesothelioma (both pleural and peritoneal) who had received at least one prior line of platinum-based chemotherapy. It was the first randomized trial to demonstrate improved overall survival in relapsed mesothelioma. Both co-primary endpoints (OS and PFS) were met. Notably, PD-L1 was not found to be predictive or prognostic in CONFIRM, suggesting that PD-L1 testing should not be used to select patients for second-line nivolumab.<ref name="confirm" /><ref name="dovepress" />

=== PROMISE-meso Trial (Phase 3, Second-Line) ===

The PROMISE-meso trial compared pembrolizumab (200 mg fixed dose every 3 weeks) versus single-agent chemotherapy (gemcitabine or vinorelbine) in 144 patients with relapsed MPM. This trial was '''negative''' — pembrolizumab did not improve progression-free survival or overall survival compared to chemotherapy in an unselected patient population. The result highlighted that single-agent PD-1 blockade is insufficient as monotherapy in second-line unselected mesothelioma and reinforced the importance of combination approaches or biomarker-driven selection.<ref name="esmo" />

=== DREAM and PrE0505 Trials (Phase 2, First-Line) ===

The '''DREAM''' trial (Australia) and '''PrE0505''' trial (United States) were single-arm phase 2 trials that tested '''durvalumab''' (anti-PD-L1) combined with standard chemotherapy (cisplatin plus pemetrexed) as first-line treatment. Both showed promising results — DREAM reported median OS of 18.4 months with a 48% objective response rate, while PrE0505 reported median OS of approximately 20.4 months with a 56.4% partial response rate. These results provided the rationale for '''DREAM3R''', a phase 3 trial of 480 patients comparing durvalumab plus chemotherapy versus chemotherapy alone.<ref name="elsevier_dream" /><ref name="ascopost_durv" /><ref name="bmjopen_dream3r" />

=== BEAT-meso Trial (Phase 3) ===

The BEAT-meso trial was an international randomized phase 3 trial comparing '''atezolizumab''' (anti-PD-L1) plus bevacizumab plus chemotherapy versus bevacizumab plus chemotherapy alone in 400 patients. The '''primary endpoint was not met''' — median OS was 20.5 months versus 18.1 months (HR 0.84, p=0.14, not significant). However, the addition of atezolizumab did significantly improve progression-free survival (9.2 vs. 7.6 months; HR 0.72, p=0.0021).<ref name="asco_beatmeso" />

== What Role Do BAP1, TMB, and Other Biomarkers Play? ==

=== BAP1 Mutations ===

'''BAP1''' (BRCA1-associated protein 1) is the most commonly mutated gene in mesothelioma, found in approximately 45.6% of cases. Other common mutations include CDKN2A (21.7%), TP53 (17.1%), and NF2 (14.3%).<ref name="asco_mutations" />

BAP1 deficiency has been found to enrich immune pathways in the tumor microenvironment, increasing interferon-alpha and interferon-gamma signatures, activating dendritic cells, and increasing checkpoint receptor expression. BAP1-deficient mesothelioma tumors may therefore be more responsive to immunotherapy, though this relationship requires further prospective validation.<ref name="bap1" />

=== Tumor Mutational Burden ===

Mesothelioma has a '''low tumor mutational burden (TMB)''' compared to other cancers that respond well to immunotherapy, such as melanoma or non-small cell lung cancer. Despite this low TMB, the CheckMate 743 results demonstrate that combination immunotherapy can still be effective. In the NIBIT-MESO-1 trial, patients with TMB higher than the median of 8.3 mutations per megabase had significantly longer survival (41.3 months vs. 17.4 months; p=0.02), suggesting TMB may help identify patients most likely to benefit.<ref name="nibit" />

== What Immunotherapy Trials Are Currently Recruiting? ==

As of January 2026, there are '''93 mesothelioma clinical trials''' actively recruiting patients, of which '''32 (34%) are immunotherapy trials''' and 52 are based in the United States.<ref name="mesowatch" />

Key actively recruiting immunotherapy trials include:

{| class="wikitable" style="width:100%; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px;" | Trial
! style="background:#1a5276; color:white; padding:10px;" | NCT Number
! style="background:#1a5276; color:white; padding:10px;" | Phase
! style="background:#1a5276; color:white; padding:10px;" | Intervention
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Neoadjuvant Durvalumab + Tremelimumab
| style="padding:10px; border-bottom:1px solid #dee2e6;" | NCT05932199
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Phase Ib/IIa
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Durvalumab + tremelimumab +/- chemo (Baylor)
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Immunotherapy Before Surgery for Sarcomatoid Meso
| style="padding:10px; border-bottom:1px solid #dee2e6;" | NCT05647265
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Phase 2
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Neoadjuvant immunotherapy + surgery
|-
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Partial Pleurectomy for Unresectable MPM
| style="padding:10px; border-bottom:1px solid #dee2e6;" | NCT07126509
| style="padding:10px; border-bottom:1px solid #dee2e6;" | —
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Surgery +/- immunotherapy
|-
| style="padding:10px;" | Pembrolizumab + Chemo + Image-Guided Surgery
| style="padding:10px;" | —
| style="padding:10px;" | Phase 2
| style="padding:10px;" | Pembrolizumab + chemo + surgery
|}

Additionally, '''5 CAR-T cell therapy trials''' are actively recruiting mesothelioma patients, representing an emerging frontier in cellular immunotherapy for this disease.<ref name="mesowatch" /><ref name="mesohope_trials" />

=== Perioperative Immunotherapy (2025 Update) ===

A phase 2 trial published in ''Nature Medicine'' (2025) evaluated neoadjuvant immunotherapy before surgery for resectable mesothelioma. Patients receiving nivolumab plus ipilimumab before surgery had a median PFS of 19.8 months and median OS of 28.6 months — substantially better than nivolumab alone (median PFS 9.6 months, median OS 19.3 months). Extended pleurectomy/decortication was performed in 81.8% of patients. These results suggest that perioperative immunotherapy may significantly improve outcomes in surgically resectable disease.<ref name="nature_periop" />

== What Does Immunotherapy Cost and How Do Patients Access It? ==

=== Cost-Effectiveness ===

A Markov model analysis from a US payer perspective found that the total cost of nivolumab plus ipilimumab treatment was approximately '''$292,319''' compared to '''$95,715''' for chemotherapy — an incremental cost of $196,604 for 0.53 additional quality-adjusted life years (QALYs). At a willingness-to-pay threshold of $207,659 per QALY, the combination was not considered cost-effective unless drug prices were reduced by approximately 34%.<ref name="costeffective" />

=== Patient Assistance Programs ===

'''BMS Access Support''' offers benefit investigation, prior authorization assistance, appeal process support, and co-pay assistance programs for eligible commercially insured patients who may pay as little as $0 per infusion, subject to an annual maximum benefit.<ref name="bms_opdivo" /><ref name="bms_pricing" />

{| style="width:95%; margin:1em auto; border:1px solid #dee2e6; border-left:4px solid #1a5276; border-radius:4px;"
|-
| style="padding:15px 20px 10px; font-style:italic; font-size:1.05em; line-height:1.5;" | "For mesothelioma patients, understanding all available treatment options — including immunotherapy clinical trials — is essential. These advances represent real hope for improved survival, particularly for those with non-epithelioid disease where chemotherapy alone offered limited benefit."
|-
| style="padding:5px 25px 20px; text-align:right;" | '''— David Foster,''' Patient Advocate, Danziger & De Llano
|}

== Related Resources ==

* [[Mesothelioma_Types|Mesothelioma Types and Histology]]
* [[Pleurectomy and Decortication|Pleurectomy and Decortication (P/D)]]
* [[Mesothelioma Diagnosis and Staging|Mesothelioma Diagnosis and Staging]]
* [[Asbestos_Health_Effects|Asbestos Health Effects]]
* [[Mesothelioma_Settlements|Mesothelioma Settlements]]


{{CTA Box|}}


== References ==
<references>
<ref name="fda">[https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma], U.S. Food and Drug Administration (2020)</ref>
<ref name="wjco">[https://www.wjgnet.com/2218-4333/full/v13/i4/267.htm Tsunami of Immunotherapy Reaches Mesothelioma], World Journal of Clinical Oncology (2022)</ref>
<ref name="lancet">[https://pubmed.ncbi.nlm.nih.gov/33485464/ First-Line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743)], Baas P et al., Lancet 2021;397:375-386</ref>
<ref name="cta">[https://www.cancertherapyadvisor.com/news/lung-cancer-nivolumab-ipilimumab-treatment-dataset-checkmate/ Full CheckMate 743 Dataset Supporting Nivolumab/Ipilimumab], Cancer Therapy Advisor</ref>
<ref name="targetedonc">[https://www.targetedonc.com/view/nivolumab-ipilimumab-improves-os-in-unresectable-malignant-pleural-mesothelioma Nivolumab/Ipilimumab Improves OS in Unresectable Malignant Pleural Mesothelioma], Targeted Oncology</ref>
<ref name="checkmate_ct">[https://clinicaltrials.gov/study/NCT02899299 CheckMate 743: Nivolumab Plus Ipilimumab vs. Chemotherapy in Mesothelioma], ClinicalTrials.gov</ref>
<ref name="cancernetwork">[https://www.cancernetwork.com/view/nivolumab-plus-ipilimumab-improves-os-in-malignant-pleural-mesothelioma Nivolumab Plus Ipilimumab Improves OS in Malignant Pleural Mesothelioma], Cancer Network</ref>
<ref name="annoncol">[https://pubmed.ncbi.nlm.nih.gov/35124183/ First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy: 3-Year Outcomes from CheckMate 743], Baas P et al., Ann Oncol 2022;33(5):488-499</ref>
<ref name="ascopost_update">[https://ascopost.com/news/february-2022/updated-efficacy-and-safety-data-from-checkmate-743-first-line-nivolumabipilimumab-vs-chemotherapy-for-unresectable-malignant-pleural-mesothelioma/ Updated Efficacy and Safety Data from CheckMate 743], The ASCO Post (2022)</ref>
<ref name="confirm">[https://pmc.ncbi.nlm.nih.gov/articles/PMC8560642/ Nivolumab Versus Placebo in Patients with Relapsed Malignant Mesothelioma (CONFIRM)], PMC/National Library of Medicine</ref>
<ref name="dovepress">[https://www.dovepress.com/an-update-on-emerging-therapeutic-options-for-malignant-pleural-mesoth-peer-reviewed-fulltext-article-LCTT An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma], Lung Cancer: Targets and Therapy, Dove Medical Press</ref>
<ref name="esmo">[https://dailyreporter.esmo.org/esmo-congress-2019/articles/immunotherapy-fails-to-improve-pfs-and-os-in-relapsed-mesothelioma Immunotherapy Fails to Improve PFS and OS in Relapsed Mesothelioma (PROMISE-meso)], ESMO Daily Reporter (2019)</ref>
<ref name="elsevier_dream">[https://linkinghub.elsevier.com/retrieve/pii/S1470204520304629 DREAM Trial: Durvalumab with First-Line Chemotherapy in Mesothelioma], Lancet Oncology / Elsevier</ref>
<ref name="ascopost_durv">[https://ascopost.com/news/june-2020/durvalumab-added-to-standard-chemotherapy-improved-os-in-patients-with-malignant-pleural-mesothelioma/ Durvalumab Added to Standard Chemotherapy Improved OS in MPM (PrE0505)], The ASCO Post (2020)</ref>
<ref name="bmjopen_dream3r">[https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2021-057663 Protocol of DREAM3R: Durvalumab with Chemotherapy as First-Line Treatment in Advanced Pleural Mesothelioma], BMJ Open</ref>
<ref name="asco_beatmeso">[https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA8002 BEAT-meso: Bevacizumab and Atezolizumab Plus Chemotherapy for Mesothelioma Phase III Results], Journal of Clinical Oncology / ASCO</ref>
<ref name="asco_mutations">[https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.8507 Association of Somatic Mutations and Histologic Subtype/Grade on Prognosis and PD-L1 Expression in Mesothelioma], JCO / ASCO (2023)</ref>
<ref name="bap1">[https://pmc.ncbi.nlm.nih.gov/articles/PMC11070913/ BAP1 Deficiency Inflames the Tumor Immune Microenvironment], PMC/National Library of Medicine</ref>
<ref name="nibit">[https://pmc.ncbi.nlm.nih.gov/articles/PMC9765708/ Tremelimumab Plus Durvalumab Retreatment and 4-Year Outcomes in Mesothelioma (NIBIT-MESO-1)], PMC/National Library of Medicine</ref>
<ref name="mesowatch">[https://mesowatch.org/news/2026/01/mesothelioma-clinical-trials-2026-landscape-report/ 93 Clinical Trials Are Recruiting People with Mesothelioma (2026)], Mesowatch</ref>
<ref name="mesohope_trials">[https://www.mesotheliomahope.com/treatment/clinical-trials/ Mesothelioma Clinical Trials: Active Recruiting Trials 2026], Mesothelioma Hope</ref>
<ref name="nature_periop">[https://www.nature.com/articles/s41591-025-03958-3 Perioperative Nivolumab or Nivolumab Plus Ipilimumab in Resectable Mesothelioma], Nature Medicine (2025)</ref>
<ref name="costeffective">[https://pmc.ncbi.nlm.nih.gov/articles/PMC9354521/ Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Treatment for Unresectable MPM], PMC/National Library of Medicine</ref>
<ref name="bms_opdivo">[https://www.opdivohcp.com/resources/patient-access-financial-support Patient Programs — OPDIVO (nivolumab)], Bristol-Myers Squibb</ref>
<ref name="bms_pricing">[https://www.bmspricinginformation.com/opdivo OPDIVO Pricing Information], Bristol-Myers Squibb</ref>
<ref name="dandell">[https://dandell.com/ Danziger & De Llano], Mesothelioma Attorneys</ref>
</references>

[[Category:Mesothelioma]]
[[Category:Medical]]
[[Category:Treatment]]
[[Category:Immunotherapy]]
[[Category:Clinical Trials]]
[[Category:FDA Approval]]